IFU, unlike some here I do not predict certain success for Bavi or Peregrine. Not yet. In my view we don't have enough data.
I don't see any harm done by the mega-optimists who talk about $20 or $50 or $1000 a PPHM share. Anyone taking that seriously has probably already lost their money on other get rich quick schemes.
On the other hand I do not understand how anyone would invest serious money in a company and question the truthfulness of its management. You and many others seem to be in that camp.
As often as I have expressed my optimism for Bavi and Peregrine management, I have also complained repeatedly that management fails to meet its shareholders reasonable expectations for information. I too have specifically complained about the lack of information on the dozens of collaborations. Unlike you I believe they exits. I am disappointed that they can't find a way to share anything about them. They don't seem to realize this just feeds doubt about the company. They just don't get it.
Meanwhile Sunrise is running around the world with hundreds of patients. We will see in months, not years, whether Peregrine has the goods or will die a slow, but sure death.
GLTA, especially Bavi-arm Sunrise patients,
Paul
Market Data 
Markets 
AI
